The Medical Advisory Secretariat (MAS) is pleased to highlight the work of staff and colleagues that have prepared publications and presentations related to the evidence-based analyses conducted by MAS and the recommendations of the Ontario Health Technology Advisory Committee. View a selection of reports from our field evaluation partners. This section will be evolving in the weeks and months to come. If you know of any items that you think should be posted, please submit to MASinfo.moh@ontario.ca.

• Reports
• Published Journal Articles and Book Chapters
• Journal Articles and Book Chapters in Press
• Published Abstracts
• Presentations/Posters
• Presentations by Dr. Les Levin, Head of Medical Advisory Secretariat

• Aronson, N, Drummond, M, and MacLeod, S. Process review and evaluation of the evidence-based health technology analysis program in Ontario. Toronto, ON: Medical Advisory Secretariat. 2008.
• Drummond, M. Determining policies for health technologies in Ontario: a process review and evaluation. Toronto, ON: Medical Advisory Secretariat. 2005.
• Ministry of Health and Long-Term Care. Accessing positron emission tomography (PET) studies/program funded by the Ministry of Health and Long-Term Care, Ontario, Canada. Toronto: The Ministry. Bulletin Number 4477; July 7, 2008. (Full Text)
• Ontario PET Steering Committee. Pet scan primer: a guide to the implementation of positron emission tomography imaging in Ontario. Toronto ON: Ministry of Health and Long-Term Care. 2008.

• Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009 Aug 18;151(4):221-8, W-48. Epub 2009 Jul 6. (Full Text). Note : Click on "Final Version" in the upper right corner of the record to view the free full text)
• Margolis ML. The PET and the pendulum. Ann Intern Med. 2009 Aug 18;151(4):279-80. Epub 2009 Jul 6. (Full Text) Note : Click on "Final Version" in the upper right corner of the record to view the free full text)
• Blackhouse G, Hopkins R, Bowen JM, DeRose G, Novick T, Tarride JE, O’Reilly D, Xie F, Goeree R. A cost-effectiveness model comparing endovascular repair to open surgical repair of abdominal aortic aneurysms in Canada. Value in Health, 2009;12(2):245-252.
• Chiu M, KO DT, Austin PC, Cohen EA, Velianou JL, Goeree R, Blackhouse G, Tu JV. Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients. Circulation: Cardiovascular Quality and Outcomes, 2009;2:96-107.
• Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O’Reilly D. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Canadian Journal of Diabetes 2009;33(1):35-45.
• O'Reilly D, Campbell K, Goeree R. Basics of health technology assessment. Programs for Assessment of Technology in Health Research Institute. Methods in Molecular Biology: 2009;473:263-83.

• Bhatti T, Baibergenova A. A comparison of the cost-effectiveness of In Vitro Fertilization strategies and Stimulated Intrauterine Insemination in a Canadian health economic model. Journal of Obstetrics and Gynecology Canada. 2008; 30(5):411-20.
• Hopkins R, Bowen J, Campbell K, Blackhouse G, DeRose G, Novick T, O’Reilly D, Goeree R, Tarride JE. Effects of study design and trends for EVAR vs. OSR. Vascular Health and Risk Management. 2008;4(5):1011-1022.
• Ko DT, Chiu M, Austin PC, Bowen J, Cohen EA, Tu JV. Safety and effectiveness of drug eluting stents among diabetic patients: A propensity analysis. American Heart Journal 2008;156:125-134.
• Kwan j, Razzaq A, Leiter L, Lillie D, Hux JE. Low socioeconomic status and absence of supplemental health insurance as barriers to diabetes care access and utilization. Canadian Journal of Diabetes.32: 174-181; 2008.
• Tarride JE, Blackhouse G, DeRose G, Novick T, Bowen JM, Hopkins R, O’Reilly D, Goeree R. Cost-effectiveness analysis of elective endovascular repair compared to open surgical repair of abdominal aortic aneurysms for patients at high surgical risk. A 1-year patient-level analysis conducted in Ontario, Canada. Journal of Vascular Surgery; 2008;48(4):779-787.

• Goeree R, O’Reilly D, Tarride J-E, Bowen J, Blackhouse G, Campbell K, Hopkins R, Lim M, Paterson L. Being led down the wrong garden PATH: the importance of knowledge and facts for the crossroads. Pharmacoeconomics 2007;25(6):528-632.
• Levin L, Goeree R, Sitich N, Jorgensen B, Brouwers M, Easty T, Zahn C, Jorgensen B. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies – The Ontario experience. International Journal of Technology Assessment in Health Care 2007;23(3):299-309.
• O’Reilly D, Hopkins R, Blackhouse G, Clarke P, Hux J, Tarride J-E, Dolovich L, Goeree R. Long-term cost-utility analysis of a multidisciplinary primary care diabetes management program in Ontario. Canadian Journal of Diabetes, 2007; 31(3):205-214.
• Sharieff, W, Kaulback, K. Assessing automated external defibrillators in preventing deaths from sudden cardiac arrest - an economic evaluation. International Journal of Technology Assessment in Health, 2007; 23(3):362–367.
• Tarride JE, Blackhouse G, DeRose G, Novick T, Bowen JM, Hopkins R, O’Reilly D, Goeree R. Cost-effectiveness analysis of elective endovascular repair compared to open surgical repair of abdominal aortic aneurysms for patients at high surgical risk. A 1-year patient-level analysis conducted in Ontario, Canada. [Letter to Editor]. Journal of Vascular Surgery, 2009;49(1): 277-278.
• Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride J-E, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. New England Journal of Medicine, 2007;357:1393-1402.

• Goeree R, Levin L. Building bridges between academic research and policy formulation: The PRUFE framework – an integral part of Ontario’s evidence-based HTPA process. PharmacoEconomics, 2006;24(11):1143-1156

• Austin PC, Chiu M, Ko DT, Goeree R, Tu J. Propensity-score matching: A tutorial and empirical example. In: Faries DE, Leon AC, Haro JM et al, eds. Analysis of Observational Health-Care Data Using SAS. Introduction to observational studies. Cary, NC: SAS Institute, Inc.
• Bowen JM, Patterson LL, O’Reilly DJ, Hopkins RB, Blackhouse G, Burke N, Xie F, Tarride JE, Goeree R. Conditionally funded field evaluations and practical trial design within a HTA framework. Journal of the American College of Radiology.
• Evans W, Laupacis A, Levine M, Gulenchyn K, Levin L. Introducing PET technology in Ontario. An approach to defining the clinical utility of a new diagnostic technology. Journal of Clinical Oncology.
• Ferrusi IL, Ames D, Lim ME, Goeree R. Health technology assessment from a Canadian device industry perspective. Journal of the American College of Radiology.
• Goeree R, Bowen JM, Blackhouse G, Lazzam C, Cohen E, Chiu M, Hopkins R, Tarride JE, Tu, JV. Economic evaluation of drug eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care.
• Goeree R, Levin L, Chandra K, Bowen JM, Blackhouse G, Tarride JE, Burke N, Bischof M, Xie F, O’Reilly D. Health technology assessment and primary data collection for reducing decision making uncertainty. Journal of the American College of Radiology.
• Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O’Reilly D. Excess risk of mortality and complications associated with newly diagnosed cases of diabetes in Ontario, Canada. Canadian Journal of Diabetes.
• Jahn B, Theurl E, Tarride J-E, Goeree R. Capacity constraints and cost-effectiveness: A discrete event simulation for drug-eluting stents. Journal of Medical Decision Making.
• Johnson AP, Sikich N.J., Evans G, Evans W, Giacomini M, Glendenning M, Krahn M, Levin L, Oh P, Perera C. Health Technology Assessment - A Comprehensive Framework for Evidence-Based Recommendations in Ontario. International Journal of Technology Assessment in Health Care.
• Lim ME, O’Reilly D, Tarride JE, Burke N, Ferrusi I, Campbell K, Goeree R. Health technology assessment for radiologists: Basic principles and evaluations framework. Journal of the American College of Radiology.
• Tarride JE, Blackhouse G, Bischof M, McCarron EC, Lim M, Ferrusi I, Xie F, Goeree R. Approaches for economic evaluations of healthcare technologies. Journal of the American College of Radiology.
• Whicher D, Chalkidou K, Dhalla I, Levin L, Tunis S. Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers. Millbank Quarterly.

• Goeree R, Lim M, O’Reilly DJ, Tarride J-E, Xie F, Bowen JM, Blackhouse G, Hopkins R. Can VOI analysis be used for setting government research agendas and priorities? Experience to date from a large province-wide initiative using an iterative VOI analysis framework. 30th Annual Meeting of the Society for Medical Decision Making. Medical Decision Making Jan/Feb, 2009;27:E95. DOI: 10.1177/0272989X0902900102012
• Goeree R, O’Reilly DJ, Tarride J-E, Xie F, Bowen JM, Blackhouse G, Hopkins R. Do technology evaluations based on evidence from conditional funding lead to an increase in policy formation? Findings from and implications of Ontario’s evidence-based HTA process. 30th Annual Meeting of the Society for Medical Decision Making. Medical Decision Making Jan/Feb, 2009;27:E21. DOI: 10.1177/0272989X0902900102012.

• Levin L, Goeree RA. Drug Eluting Stents – An example of the transition from evidence to policy through the Ontario comprehensive approach to the diffusion of health technologies. Value in Health, 2008;11(3):A1
• Lim ME, Bowen J, McCarron CE, Blackhouse G, Hopkins R, O’Reilly D, Goeree RA, Tarride JE. The CADTH guidelines for the economic evaluation of health technologies: do current Canadian economic evaluations pass the test. Value in Health, 2008;11(3):June:A51.
• Maziak, D, Darling GE, , R. I. Inculet, RI, K. Gulenchyn, K, A. A. Driedger, AA, Y. C. Ung, YC, J. D. Miller JD, Koru-Sengul, T, Evans, WK, Levine. MN. A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 26: (May 20 suppl; abstr 7502); 2008.
• Pritchard KI, Julian J, McCready D, Holloway C, Gulenchyn K, Hodgson N, Lovrics P, Down N, George R, Levine MN. J. A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer. J. Clin Oncol. 26 (May 20 suppl; abstr 533); 2008.

• O'Reilly D, Hopkins R, Blackhouse G, Clarke P, Hux J, Tarride JE, Dolovich L, Goeree R. Long-term cost utility analysis of a multifaceted primary care diabetes management program in Ontario. Canadian Journal of Clinical Pharmacology; 14(2) Summer 2007:e147.
• O’Reilly D, Blackhouse G, Tarride JE, Bowen J, Goeree R. A systematic review and meta-analysis of rosiglitazone and pioglitazone for the treatment of type 2 diabetes mellitus in adults. Canadian Journal of Clinical Pharmacology; 14(2) Summer 2007:e147.
• Tarride JE, Bowen J, Blackhouse G, Hopkins R, O’Reilly D, Goeree R. Cost effectiveness of drug eluting stents (DES) compared to bare metal stents (BMS) in Ontario. Canadian Journal of Clinical Pharmacology; 14(2) Summer 2007:e106.
• Tarride JE, Bowen J, DeRose G, Blackhouse G, Hopkins R, Novick T, O’Reilly D, Goeree R. A patient-level economic evaluation of elective endovascular repair (EVAR) of non-ruptured abdominal aortic aneurysms (AAA) compared to open surgical repair (OSR) in high risk patients. Canadian Journal of Clinical Pharmacology; 14(2) Summer 2007:e146.

• Blackhouse G, Bowen J, Tarride JE, Hopkins R, O’Reilly D, Goeree R. Cost effectiveness of drug eluting stents in Ontario (#39). The Canadian Journal of Clinical Pharmacology, 2006;13(1):e147.
• Blackhouse G, Bowen J, Tarride JE, Hopkins R, O'Reilly D, Goeree R. Cost effectiveness of drug eluting stents (DES) compared to bare metal stents (BMS) using "real world" data. Value in Health, 2006;9(3):A8.
• Goeree R, Bowen J, DeRose G, Hopkins R, Novick T, Blackhouse G, O'Reilly D, Tarride JE. Cost-utility of elective endovascular repair (EVAR) compared to open surgical repair (OSR) of abdominal aortic aneurysms (AAA). Value in Health, 2006;9(3):A173.
• O’Reilly D, Clark P, Hopkins R, Hux J, Tarride JE, Blackhouse G, Goeree R. The immediate and long-term costs of diabetes and diabetes-related complications: Results from a large prospective cohort study (#109). The Canadian Journal of Clinical Pharmacology, 2006;13(1):e181.
• O'Reilly D, Clarke P, Hopkins R, Hux J, Tarride JE, Blackhouse G, Goeree R. Improving the measurement of the cost of diabetes and diabetes-related complications: results from a large prospective cohort study. Value in Health, 2006;9(3):A36.
• O'Reilly D, Clarke P, Hopkins R, Hux J, Tarride JE, Blackhouse G, Goeree R. Modelling lifetime healthcare costs and consequences of a nurse-led multifaceted intervention to improve the management of patients with diabetes: results from a computerized simulation model. Value in Health, 2006;9(3):A33.
• Tarride JE, Bowen J, DeRose G, Hopkins R, Novick T, Blackhouse G, Goeree R. Elective endovascular repair (EVAR) compared to open surgical repair (OSR) of abdominal aortic aneurysms (AAA): A cost-utility analysis (#58). The Canadian Journal of Clinical Pharmacology, 2006;13(1):e157.

• Khan T, Bornstein M, Chandra K, Gomes T, McMartin K, Pron G. Aging in the community: integrating multiple systematic reviews around healthy aging to inform policy decision making in Ontario, 7th Annual Canadian Cochrane Symposium, Halifax, NS, March 11-12, 2009. (Oral).
• O’Reilly D, Xie F, Pullenayegum E, Gerstein H, Blackhouse G, Tarride J-E, Bowen J, Goeree R. Estimation of utility values for diabetes-related complications on quality of life for patients with type 2 diabetes in Ontario, Canada. ISPOR 14th Annual International Meeting, Orlando, FL, USA. May 16-20, 2009.

• Bhatti T, Sehatzedeh S, Burke N, Whelan JP, Goeree R, Tarride JE. Cost of treatment of benign prostatic hyperplasia (BPH) in Ontario and implications for policy recommendations. 63rd Annual Meeting of the Canadian Urological Association (CUA), Edmonton, AB. June 22-25, 2008.
• Bhatti T, Sehatzadeh S, Burke N, Whelan JP, Goeree R, Tarride JE. Energy-delivery systems for the surgical treatment of BPH: Cost and implications for policy recommendations in Ontario, Canada. Northeastern American Urological Association (AUA) annual meeting, Santa Ana Pueblo, NM September 17-21, 2008.
• Bowen JM, O’Reilly D, Patterson L, Hopkins RB, Nunes E, MacDougald C, Assasi N, Blackhouse G, Burke N, Campbell K, Tarride JE, Xie F, Goeree R. The PATH to decisions for new and existing health technologies. St. Michael’s Hospital Wound Healing and Skin Ulcer Prevention Program Conference: Building Bridges II: Discovering, navigating and integrating knowledge for safer wound care. Niagara-on-the-Lake, ON. November 21-23, 2008 (Oral).
• Bowen JM, O’Reilly DJ, Xie F, Tarride JE, Blackhouse G, Hopkins RB, Campbell K, Burke N, Assasi N, Goeree R. Health technology assessment: an overview. Presented at the 2008 Annual Scientific Meeting of the Canadian Society of Nuclear Medicine, Toronto, ON. April 24, 2008.
• Goeree R, O’Reilly D, Tarride JE, Xie F, Bowen J, Blackhouse G, Hopkins R. Do technology evaluations based on evidence from conditional funding lead to increased policy formation?: Findings from Ontario’s evidence-based HTA process. SMDM 30th Annual International Meeting, Philadelphia, PA. October 22, 2008 (Oral).
• Goeree R, Lim M, O’Reilly D, Tarride JE, Xie F, Bowen J, Blackhouse G, Hopkins R. Can VOI analyses be used for setting government research agendas and priorities?: Experience from a province-wide initiative using an iterative VOI analysis framework. SMDM 30th Annual International Meeting, Philadelphia, PA. October 18-22, 2008 (Poster)
• Goeree R. Do technology evaluations based on evidence from conditional funding lead to an increase in policy formation?: Findings from, and implications of Ontario’s evidence-based HTA process. ISPOR 11th Annual European Congress, November 10, 2008, Athens, Greece. (Oral).
• Goeree R, Tarride JE, O’Reilly D, Xie F, Bowen J, Blackhouse G, Hopkins R, Campbell K, Burke N, Lim M. Using HTA to inform publicly financed health care decision-making: The case study of drug eluting stents in Ontario, Canada. HTAi Conference, Montreal, PQ, July 6, 2008.
• Goeree R, Tarride JE, O’Reilly D, Xie F, Bowen J, Blackhouse G, Hopkins R, Campbell K, Burke N, Lim M. Using conditionally funded field evaluations (CFFE) for evidence development, uncertainty reduction and reimbursement decision making: Case studies from Ontario. HTAi Conference, Montreal, PQ, July 10, 2008.
• Khan T, Chandra K. Low-density lipoprotein apheresis for the treatment of familial hypercholesterolemia: a review. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 13th Annual Meeting, Toronto, ON, May 3-7, 2008. (Poster).
• Khan T, Chandra K. Low-density lipoprotein apheresis for the treatment of familial hypercholesterolemia: a review. Health Technology Assessment International (HTAi), 5th Annual Meeting, Montreal, PQ, July 6-9, 2008. (Poster).
• Levin L, Goeree R. Drug Eluting Stents: An example of the transition from evidence to policy through the Ontario comprehensive approach to the diffusion of health technologies. ISPOR 13th Annual International Meeting, Toronto, ON. May 3-7, 2008. (Oral).
• O’Reilly D, Blackhouse G, Hopkins R, Bowen JM, Xie F, Tarride JE, Goeree R. The long-term costs and consequences of various diabetes management strategies: Results from the Ontario diabetes economic model (ODEM). Presentation at the Canadian Diabetes Association / Canadian Society of Endocrinology and Metabolism Professional Conference, October 16, 2008, Montreal, PQ (Oral).
• Whelan JP, Sehatzedeh S, Burke N, Goeree R, Tarride JE. Assessment of energy delivery systems for the treatment of benign prostatic hyperplasia (BPH): A meta-analysis of existing randomized controlled trials. 63rd Annual Meeting of the Canadian Urological Association (CUA), Edmonton, AB. June 22-25, 2008.
• Whelan JP, Sehatzadeh S, Burke N, Goeree R, Tarride JE. Systematic review and meta-analysis of energy-based interventions for the surgical treatment of benign prostatic hyperplasia (BPH). Northeastern American Urological Association (AUA) annual meeting, Santa Ana Pueblo, NM September 17-21, 2008.

• Bowen J, Tarride JE, O’Reilly DJ, Blackhouse G, Hopkins RB, Campbell K, Lim M, Burke N, Goeree R. Determining the effectiveness of new health technologies in Ontario. Presentation to Medical Devices Forum, St. Andrew’s Club and Conference Centre, Toronto, ON. March 8, 2007.
• Bowen JM, Hopkins R, Chiu M, Blackhouse G, Lazzam C, Ko D, Tu JV, Cohen E, Campbell, K, He Y, Willan A, Tarride JE, Goeree R. Clinical and cost-effectiveness analysis of drug eluting stents (DES) compared to bare metal stents (BMS) for percutaneous coronary interventions (PCI) in Ontario. ESC Forum on Drug Eluting Stents, European Heart House, Nice, France, September 28, 2007.
• Campbell K, Bowen JM, Tarride JE, O’Reilly DJ, Blackhouse G, Hopkins RB, Lim M, Burke N, Goeree R. Introduction to Health Technology Assessment (HTA) at the Program for Assessment of Technology in Health (PATH), Golden Horseshoe Health Libraries Association (GHHLA) Meeting, St. Joseph’s Mountain Healthcare, Hamilton, ON. March 29, 2007.
• DeRose G, Bowen J, Blackhouse G, T, Forbes TL, Lawlor DK, Harris KA, Goeree R. Cost-effectiveness analysis of elective endovascular repair compared to open surgical repair of abdominal aortic aneurysms. Canadian Society for Vascular Surgery, 29th Annual Meeting, Montreal, PQ, September 28-29, 2007. (Oral).
• Hopkins R, O'Reilly D, Blackhouse G, Tarride JE, Bowen J, Campbell K, Patterson L, Goeree R. Potential systematic bias in the estimation of cost-effectiveness that result from using non disease-specific costs: demonstration with a population-based diabetes and matched non-diabetes cohort in the province of Ontario. SMDM 29th Annual Meeting, Pittsburgh, PA, October 24, 2007. (Poster).
• O’Reilly D, Hopkins R, Blackhouse G, Clarke P, Hux J, Tarride JE, Dolovich L, Goeree R. Long-term cost utility analysis of a multifaceted primary care diabetes management program in Ontario. 4th Canadian Therapeutics Congress (CAPT), Halifax, NS, May 27-30, 2007. (Poster).
• O’Reilly D, Blackhouse G, Tarride JE, Bowen J, Goeree R. A systematic review and meta-analysis of rosiglitazone and pioglitazone for the treatment of type 2 diabetes mellitus in adults. 4th Canadian Therapeutics Congress (CAPT), Halifax, NS, May 27-30, 2007. (Poster).
• Tarride JE, Bowen J, Blackhouse G, Hopkins R, O’Reilly D, Goeree R. Cost-effectiveness of drug eluting stents (DES) compared to bare metal stents (BMS) in Ontario. 4th Canadian Therapeutics Congress (CAPT), Halifax, NS, May 27-30, 2007. (Oral) [Top rated abstract]
• Tarride JE, Bowen J, DeRose G, Blackhouse G, Hopkins R, Novick T, O’Reilly D, Goeree R. A patient-level economic evaluation of elective endovascular repair (EVAR) of non-ruptured abdominal aortic aneurysms (AAA) compared to open surgical repair (OSR) in high risk patients. 4th Canadian Therapeutics Congress (CAPT), Halifax, NS, May 27-30, 2007. (Oral)

• Blackhouse G, Bowen J, Tarride JE, Hopkins R, O'Reilly D, Goeree R. Cost effectiveness of drug eluting stents (DES) compared to bare metal stents (BMS) using "real world" data. ISPOR 11th Annual International Meeting, Philadelphia, PA. May 23, 2006 (Oral presentation) [Awarded Best Podium Presentation Award.]
• Blackhouse G, Bowen J, Tarride JE, Hopkins R, O'Reilly D, Goeree R. Cost effectiveness of drug eluting stents in Ontario. CAPT at the 3rd Annual Canadian Joint Therapeutics (CAPT) Congress, Toronto, ON. May 10-11, 2006. (Poster).
• Bowen J, Hopkins R, Blackhouse G, Tarride JE, O’Reilly D, Burke N, Goeree R. Evaluation of non-drug technologies in Ontario: A new paradigm. CAPT at the 3rd Annual Canadian Joint Therapeutics (CAPT) Congress, Toronto, ON. May 10-11, 2006.
• Bowen J, Blackhouse G, Hopkins R, He Y, Lazzam C, Tu J, Cohen E, Tarride J, Goeree R. Using “real-world” data to evaluate the cost-effectiveness of drug eluting stents (DES) compared to bare metal stents (BMS). Society for Medical Decision Making. 2006. Available at http://smdm.confex.com/smdm/2006ma/techprogram/P3128.HTM
• Goeree R, Blackhouse G, Bowen J, Burke N, Hopkins R, O’Reilly D, Tarride J. Z academic research and policy formulation in health technology assessment. The PRUFE framework. 28th Annual Meeting of the Society for Medical Decision Making, Cambridge, MA, October 14-18, 2006 (Poster).
• Goeree R, Bowen J, Tarride JE, Blackhouse G, O'Reilly D, Hopkins R. Field evaluations for reducing uncertainty in decision making: what are they, how can they be used, and are they useful? CCOHTA Invitational Symposium, Ottawa, ON. April 3, 2006.
• Goeree R, Bowen J, Hopkins R, He Y, Blackhouse G, Lazzam C, Tu J, Cohen E, Tarride JE. Cost-effectiveness analysis of drug eluting stents (DES) compared with bare metal stents (BMS) based on an Ontario field evaluation. CCOHTA Invitational Symposium, Ottawa, ON. April 3-4, 2006 (Poster).
• Goeree R, Bowen J, Hopkins R, Blackhouse G, Tarride JE, Novick T, DeRose G. An economic evaluation of elective endovascular repair (EVAR) compared with open surgical repair (OSR) of abdominal aortic aneurysms (AAA). CCOHTA Invitational Symposium, Ottawa, ON. April 3-4, 2006. (Poster). Available at http://smdm.confex.com/smdm/2006ma/techprogram/P3066.HTM
• Goeree R. Building bridges between academic research and policy formulation: The PRUFE Framework. A conference in honour of Bernie J. O’Brien. McMaster University, Hamilton, ON. June 19-20, 2006.
• Goeree R, Bowen J, DeRose G, Hopkins R, Novick T, Blackhouse G, O'Reilly D, Tarride JE. Cost-utility of elective endovascular repair (EVAR) compared to open surgical repair (OSR) of abdominal aortic aneurysms (AAA). ISPOR 11th Annual International Meeting, Philadelphia, PA. May 20-24, 2006. (Poster).
• Goeree R, Blackhouse G, Bowen J, Burke N, Hopkins R, O’Reilly D, Tarride J. Building bridges between academic research and policy formulation in health technology assessment. The PRUFE framework. 28th Annual Meeting of the Society for Medical Decision Making, Cambridge, Massachusetts, October 14-18, 2006. Available at: http://smdm.confex.com/smdm/2006ma/techprogram/P3054.HTM
• Jahn B, Theurl E, Goeree R, Bowen J, Blackhouse G, Hopkins R, Tarride JE. Discrete event simulation: An approach that challenges traditional modeling methods? An illustration using drug eluting stents. ISPOR 9th Annual European Congress, Copenhagen, Denmark, October 28-31, 2006. (Poster).
• Levin L, Goeree R. Economic evaluation in Ontario’s health technology policy analysis. Better Analysis for Better Decisions: Bridging the gap between economic evaluation and healthcare decision making. A conference in honour of Bernie J. O’Brien. McMaster University, Hamilton, ON. June 19-20, 2006.
• O'Reilly D, Clarke P, Hopkins R, Hux J, Tarride JE, Blackhouse G, Goeree R. The immediate and long-term costs of diabetes and diabetes-related complications: results from a large prospective cohort study. CAPT at the 3rd Annual Canadian Joint Therapeutics Congress, Toronto ON. May 10-11, 2006. (Poster).
• O'Reilly D, Clarke P, Hopkins R, Hux J, Tarride JE, Blackhouse G, Goeree R. Improving the measurement of the cost of diabetes and diabetes-related complications: results from a large prospective cohort study. ISPOR 11th Annual International Meeting, Philadelphia, PA. May 20-24, 2006. (Poster).
• O’Reilly D, Clarke P, Hopkins R, Hux J, Blackhouse G, Tarride J, Bowen J, Goeree R. The incidence and cost of diabetes and diabetes-related complications in Canada: results from a large prospective cohort study. 28th Annual Meeting of the Society for Medical Decision Making, Cambridge, MA, October 14-18, 2006 (Oral) [Awarded Top Rated Abstract.]. Available at http://smdm.confex.com/smdm/2006ma/techprogram/P3065.HTM
• O'Reilly D, Clarke P, Hopkins R, Hux J, Tarride JE, Blackhouse G, Goeree R. Modelling lifetime healthcare costs and consequences of a nurse-led multifaceted intervention to improve the management of patients with diabetes: results from a computerized simulation model. ISPOR 11th Annual International Meeting, Philadelphia, PA. May 20-24, 2006 (Poster).
• O’Reilly D, Clarke P, Hopkins R, Hux J, Blackhouse G, Dolovich L, Tarride J, Goeree R. Development and application of a diabetes economic model. 28th Annual Meeting of the Society for Medical Decision Making, Cambridge, MA, October 14-18, 2006 (Oral). Available at http://smdm.confex.com/smdm/2006ma/techprogram/P2709.HTM
• Tarride JE, Bowen J, DeRose G, Hopkins R, Novick T, Blackhouse G, Goeree R. Elective endovascular repair (EVAR) compared to open surgical repair (OSR) of abdominal aortic aneurysms (AAA): a cost-utility analysis. CAPT at the 3rd Annual Canadian Joint Therapeutics Congress, Toronto, ON. May 10-11, 2006. (Poster).
• Tarride J, Bowen J, DeRose G, Blackhouse G, Hopkins R, Novick T, Goeree R. An economic evaluation of elective endovascular repair (EVAR) of non-ruptured abdominal aortic aneurysms (AAA) compared to open surgical repair (OSR). 28th Annual Meeting of the Society for Medical Decision Making, Boston, MA, USA. October 14-18, 2006 (Poster).

• Submission accepted to lead a session of 7 speakers (3 from Medical Advisory Secretariat, 1 from THETA, 1 from Australia and 1 from the United Kingdom) on Mega-analysis. HTAi meeting in Singapore; June 2009
• Closed meeting on conditional funding on evidence development. University of Alberta, Banff AB Canada; February 2009

• Canadian College of Health Service Executives, Miami, FL.; December 2008.
• National Physician Managers, Blue Cross Blue Shield Chicago, Il; December 2008.
• Opening plenary presentation to Asian Pacific Meeting on Policy Development for Health Technologies in Shanghai, China.; October 2008.
• NHS Quality Improvement Scotland, Scottish Medicines Consortium and University of Glasgow, Coverage with Evidence Development in Glasgow, Scotland.; September 2008.
• University of British Columbia and Coastal Regional Health Authority presentation on Ontario’s approach to Evidence Based Decision Making for Health Technologies in Vancouver, B.C.; September 2008.
• National Academy of Sciences Institute of Medicine Symposium on “What Works in Health Care” in Washington, D.C.; July 2008.
• HTAi International Annual Meeting, Plenary Session on Conditional Funding for Health Technologies, HTA methodologies session in Montreal, Que.; July 2008. (Download this presentation)
• Annual meeting of MEDEC, the Interface between Evidence Based Analysis and Industry/Academia Driven Innovation. Toronto, Ontario; June 2008
• NICE/AHRQ Invitational Working Group “Addressing Uncertainty in Evidence Based Analysis in London, England; May 2008
• Invitational International Working Group on HTA in Banff, AB; November 2007

© Queen's Printer for Ontario, 2002  |  Privacy Policy  |  Disclaimers  |   Last Modified :